Silo Pharma Inc (SILO) - Total Assets
Based on the latest financial reports, Silo Pharma Inc (SILO) holds total assets worth $5.95 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Silo Pharma Inc - Total Assets Trend (2010–2025)
This chart illustrates how Silo Pharma Inc's total assets have evolved over time, based on quarterly financial data. Also see Silo Pharma Inc stock valuation for the company's overall valuation and market capitalisation.
Silo Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Silo Pharma Inc's total assets of $5.95 Million consist of 97.1% current assets and 2.9% non-current assets. Review SILO total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 62.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $217.38K | 2.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Silo Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Silo Pharma Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Silo Pharma Inc's current assets represent 97.1% of total assets in 2025, a decrease from 100.0% in 2010.
- Cash Position: Cash and equivalents constituted 62.4% of total assets in 2025, down from 100.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 2.9% of total assets.
Silo Pharma Inc Competitors by Total Assets
Key competitors of Silo Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Silo Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.36 | 6.07 | 39.88 |
| Quick Ratio | 5.36 | 6.07 | 40.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.65 Million | $5.32 Million | $11.02 Million |
Silo Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Silo Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.83 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | 2.6% |
| Total Assets | $7.61 Million |
| Market Capitalization | $3.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Silo Pharma Inc's assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Silo Pharma Inc's assets grew by 2.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Silo Pharma Inc (2010–2025)
The table below shows the annual total assets of Silo Pharma Inc from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.61 Million | +2.61% |
| 2024-12-31 | $7.41 Million | -4.32% |
| 2023-12-31 | $7.75 Million | -33.47% |
| 2022-12-31 | $11.64 Million | +10.99% |
| 2021-12-31 | $10.49 Million | +635.29% |
| 2020-12-31 | $1.43 Million | +188.89% |
| 2019-12-31 | $493.85K | -42.27% |
| 2018-12-31 | $855.42K | -47.88% |
| 2017-12-31 | $1.64 Million | +26.30% |
| 2016-12-31 | $1.30 Million | -46.96% |
| 2015-12-31 | $2.45 Million | -11.59% |
| 2014-12-31 | $2.77 Million | +25.56% |
| 2013-12-31 | $2.21 Million | +791077.06% |
| 2012-12-31 | $279.00 | -84.08% |
| 2011-12-31 | $1.75K | -96.31% |
| 2010-12-31 | $47.48K | -- |
About Silo Pharma Inc
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's… Read more